Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1236244 | 0.87 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906310 | 0.86 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906313 | 0.86 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906306 | 0.86 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2910537 | 0.85 | SPPL2A (0.65) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2910535 | 0.85 | SPPL2A (0.65) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2910534 | 0.85 | SPPL2A (0.65) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906364 | 0.83 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906368 | 0.83 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL28799797 | 0.83 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143421-B2 | Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-03-27 | — | — | US | disclosed |
| EP-1485358-B1 | BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARM LTD (IE) | 2011-02-02 | — | — | EP | disclosed |
| US-20090203743-A1 | SMALL MOLECULE ENTRY INHIBITORS | SURLERAUX DOMINIQUE LOUIS | 2009-08-13 | — | — | US | disclosed |
| US-20050171175-A1 | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD (IE) | 2005-08-04 | — | — | US | disclosed |
| EP-1485358-A1 | BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076413-A1 | BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203743-A1 | SMALL MOLECULE ENTRY INHIBITORS | NR0B1, LTC4S, LTB4R | SPPL2A 2682/4885MLNR 1243/4885ABCB11 315/4885 |
| US-20050171175-A1 | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors | CYP2S1, CYP2C8, PRSS8 | SPPL2A 1494/4885MLNR 1989/4885ABCB11 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.